Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$307.80 USD

307.80
3,427,831

+6.66 (2.21%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $307.00 -0.80 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 34% (175 out of 247)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ongoing Procedural Growth May Aid Stryker's (SYK) Q1 Earnings

by Zacks Equity Research

Stryker's (SYK) first-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Zacks Equity Research

Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.

Zacks Equity Research

Henry Schein (HSIC) Global Presence Aids, Macroeconomic Woes Stay

by Zacks Equity Research

Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.

Zacks Equity Research

Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition

by Zacks Equity Research

Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Zacks Equity Research

Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail

by Zacks Equity Research

Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.

Zacks Equity Research

Why You Should Add Haemonetics (HAE) to Your Portfolio Now

by Zacks Equity Research

Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors' optimism for Haemonetics (HAE).

Zacks Equity Research

Smith+Nephew (SNN) Expands in Australia With New Alliance

by Zacks Equity Research

The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.

Zacks Equity Research

Align Technology (ALGN) Up 20.5% YTD: Will the Rally Continue?

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) driven by geographic expansion and upbeat guidance.